Pay in 4 interest-free payments of $6.69 Learn more
Ships within 48 hours Β· Estimated delivery Sep 4 - Sep 9
2011 hip-fracture trial, which prompted the study's early termination
Seino, S
We are currently amid an evolving revolution in obesity pharmacotherapy, with increasingly efficacious anti-obesity medicines (AOMs), incorporating uni-, bi- and trimolecular incretin receptor agonists [8, 9]
When managed correctly, the benefits extend to your entire organ system
If metformin at a maximum tolerated dose does not achieve the HbA1c target after 3 months, add a second oral agent (a sulfonylurea [SU], thiazolidinedione [TZD], dipeptidyl peptidase 4 [DPP-4] inhibitor, or sodium-glucose cotransporter-2 [SGLT2] inhibitor), a glucagon-like peptide-1 (GLP-1) receptor agonist, or a basal insulin ( TABLE 2 )
doi: 10.1111/dom.15872 58 SuyamaTShimizuMKumikoM
US$ 28.50
US$ 23.86
US$ 28.45
US$ 27.91
